Rhodes Jason P sold DYN
July 6, 2026 · Form 4 insider transaction
Rhodes Jason P sold 100,019 shares of Dyne Therapeutics, Inc. at $22.79 per share, a transaction worth $2.28M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.; The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.4163 to $23.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6) through (8).; The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.